



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box 801
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/674,067	Christoph Huls	50186/003001

RECEIVED**MAY 24 2002****CLARK & ELBING LLP**

Karen L Elbing
 Clark & Elbing
 176 Federal Street
 Boston, MA 02110

INTERNATIONAL APPLICATION NO.	
PCT/EP99/03071	
I.A. FILING DATE	PRIORITY DATE
05/05/1999	05/08/1998

CONFIRMATION NO. 9272**371 FORMALITIES LETTER**

OC00000008111770

Date Mailed: 05/15/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Biochemical Sequence Listing
- Claims
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Drawings
- Information Disclosure Statements
- Initial Application Filing Fees
- Oath or Declaration
- Oath or Declaration
- Original Specification
- Preliminary Amendments
- Request for Immediate Examination

ACTION DUE Sequence Listing
 DUE DATE 6/15/02
 INITIALS dmm

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

o The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- ▣ A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).
- ▣ APPLICANT MUST PROVIDE:
 - ▣ An initial or substitute computer readable form (CRF) of the "Sequence Listing."
 - ▣ A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).

o For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:

- ▣ For Rules Interpretation, call (703) 308-4216
- ▣ To Purchase PatentIn Software, call (703) 306-2600
- ▣ For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

- ▣ A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 CFR 1.821(e).

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

VONDA M WALLACE

Telephone: (703) 305-3736

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/674,067	PCT/EP99/03071	50186/003001